Comparative Effectiveness of Pharmacologic Interventions for Pulmonary Arterial Hypertension A Systematic Review and Network Meta-Analysis
Jain S, Khera R, Girotra S, Badesch D, Wang Z, Murad MH, Blevins A, Schmidt GA, Singh S, Gerke AK. Comparative Effectiveness of Pharmacologic Interventions for Pulmonary Arterial Hypertension A Systematic Review and Network Meta-Analysis. CHEST Journal 2016, 151: 90-105. PMID: 27615023, PMCID: PMC5310124, DOI: 10.1016/j.chest.2016.08.1461.Peer-Reviewed Original ResearchConceptsPulmonary arterial hypertensionEndothelin receptor antagonistsArterial hypertensionPharmacologic interventionsFunctional statusNew York Heart Association/World Health Organization functional classWorld Health Organization functional classSystematic reviewFuture comparative-effectiveness trialDiscontinuation of therapyA Systematic ReviewComparative effectiveness trialNetwork Meta-AnalysisPatient-centered approachClinical worseningCochrane RegisterSubcutaneous prostanoidsEfficacy outcomesPlacebo groupPlacebo ratesAdverse eventsReceptor antagonistPharmacologic agentsEffectiveness trialComparative efficacyAssociation of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis
Khera R, Murad MH, Chandar AK, Dulai PS, Wang Z, Prokop LJ, Loomba R, Camilleri M, Singh S. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. JAMA 2016, 315: 2424-2434. PMID: 27299618, PMCID: PMC5617638, DOI: 10.1001/jama.2016.7602.Peer-Reviewed Original ResearchConceptsAdverse eventsClinical trialsWeight lossObese adultsHigher oddsAdverse event-related treatment discontinuationSystematic reviewSignificant excess weight lossCumulative ranking (SUCRA) probabilitiesDiscontinuation of therapyExcess weight lossProportion of patientsManagement of obesityQuality of evidenceWeight loss agentsWeb of ScienceTreatment discontinuationCochrane CENTRALPharmacological treatmentMagnitude of decreaseGRADE criteriaDrug treatmentLiraglutideMAIN OUTCOMEPlacebo participants